Synlett 2003(6): 0743-0767
DOI: 10.1055/s-2003-38724
ACCOUNT
© Georg Thieme Verlag Stuttgart ˙ New York

Towards an Oligosaccharide-Based Glycoconjugate Vaccine Against Shigella dysenteriae Type 1

Vince Pozsgay*a, Bruce Coxona, Cornelis P. J. Glaudemansb, Rachel Schneersona, John B. Robbinsa
a National Institute of Child Health and Human Development, National Institute of Health, 6 Center Dr., MSC 2720, Bethesda, MD 20892-2720, USA
Fax: +1(301)2951435; e-Mail: vipo@helix.nih.gov;
b National Institute of Diabetes, Digestive, and Kidney Diseases, National Institute of Health, 6 Center Dr., MSC 2720, Bethesda, MD 20892-2720, USA
Further Information

Publication History

Received 31 May 2002
Publication Date:
17 April 2003 (online)

Abstract

This review summarizes the authors’ studies in the past decade aimed at developing a synthetic oligosaccharide-based glycoconjugate vaccine to prevent a serious human disease caused by the Gram negative bacterium Shigella dysenteriae type 1. Starting from simple monosaccharides, oligosaccharides as large as a 24 monosaccharide-containing linear polymer, were assembled. Under suitable conditions, oligosaccharides containing 4 to 16 hexopyranose residues were covalently attached to an immunogenic protein. The serum response to the synthetic glycoconjugates depends, both on the size of the oligosaccharides, and on the molar ratio of the oligosaccharides to the carrier protein. Also reviewed are studies of the fine specificities of the interaction between oligosaccharides and anti-polysaccharide monoclonal antibodies as well as conformational studies of the synthetic oligosaccharides.

  • 1 Polysaccharide-Based Vaccines

  • 1.1 Surface Polysaccharides of Bacteria

  • 1.2 Immunologic Properties of Polysaccharides

  • 1.3 Polysaccharide-Protein Conjugates

  • 1.3.1 Methods for the Conjugation of Polysaccharides to Proteins

  • 1.3.2 Immunogenicity of Polysaccharide-Protein Conjugates

  • 1.4 Synthetic Oligosaccharides Can be Superior to Natural Polysaccharides for Glycoconjugate Vaccines

  • 1.5 Potentials of the O-Specific Polysaccharides of Shigellae for Vaccine Development

  • 2 Chemical Synthesis of Oligosaccharides Related to the
    O-Specific Polysaccharide of S. dysenteriae Type 1

  • 2.1 General Strategy

  • 2.2 Synthesis of the Monosaccharide Building Blocks

  • 2.2.1 The l-Rhamnose Moiety

  • 2.2.2 The d-Galactose Moiety

  • 2.2.3 The d-Glucosamine Synthons

  • 2.3 Synthesis of a Complete Repeating Unit

  • 2.4 Construction of Extended Oligosaccharides

  • 2.5 The Lipophilic Protecting Group-Based Approach to
    Oligosaccharides

  • 3 Covalent Attachment of the Oligosaccharides to Human
    Serum Albumin

  • 3.1 Conjugation through a Secondary Spacer, Using Reductive Amination

  • 3.2 Conjugation through Diels-Alder Cycloaddition Reactions

  • 4 The Molecular Specificity of the Non-Covalent Binding
    between O-Specific Polysaccharide-Specific Antibodies
    and Oligosaccharides Related to the O-Specific
    Polysaccharide

  • 5 Conformational Studies

  • 6 Immunogenicity of the Protein Conjugates of the Synthetic
    Oligosaccharides in Mice

  • 7 Conclusions and Future Prospects

    References

  • 1 For a concise overview of polysaccharide-based antibacterial vaccines and a review of oligosaccharide-protein conjugates as vaccine candidates see: Pozsgay V. Adv. Carbohydr. Chem. Biochem.  2001,  56:  153 
  • 2 Robbins JB. Schneerson R. Anderson P. Smith DH. J. Am. Med. Assoc.  1996,  276:  1181 
  • 3 Sutton A. Schneerson R. Kendallmorris S. Robbins JB. Infect. Immun.  1982,  35:  95 
  • 4 Liang-Takasaki CJ. Grossman N. Leive L. J. Immunol.  1983,  130:  1867 
  • 5 Robbins JB. Chu C. Schneerson R. Clin. Infect. Dis.  1992,  15:  346 
  • 6 Robbins JB. Schneerson R. Szu SC. J. Infect. Dis.  1995,  171:  1387 
  • 7 Fothergill LD. Wright J. J. Immunol.  1933,  24:  273 
  • 8 Goldschneider I. Gotschlich EC. Artenstein MS. J. Exp. Med.  1969,  129:  1307 
  • 9 Schneerson R. Robbins JB. N: Engl. J. Med.  1975,  292:  1093 
  • 10 Robbins JB. Schneerson R. Glode MP. Vann WF. Schiffer MS. Liu T.-Y. Parke JC. Huntley C. J. Allergy Clin. Immunol.  1975,  56:  141 
  • 11 Robbins JB. Schneerson R. Gotschlich EC. Pediatr. Infect. Dis. J.  2000,  19:  945 
  • 12 Landsteiner K. The Specificity of Serological Reactions   Harvard University Press; Cambridge MA: 1945. 
  • 13 Goebel WF. Avery OT. J. Exp. Med.  1929,  50:  521 
  • 14 Goebel WF. J. Exp. Med.  1939,  69:  353 
  • 15 Goebel WF. J. Exp. Med.  1940,  72:  33 
  • 16 Peeters CCAM. Lagerman PR. de Weers O. Ooemn LA. Hoogerhout P. Beurret M. Poolman JT. In Vaccine Protocols   Robinson A. Farrar G. Wiblin C. Humana Press Inc.; Totowa N.J.: 1996.  p.111-133 
  • 17 Dick WE. Beurret M. Contrib. Microbiol. Immunol.  1989,  10:  48 
  • 18 Jennings HJ. Sood R. In K. Neoglycoconjugates. Preparation and Applications   Lee YC. Lee RT. Academic Press; New York: 1994.  p.325-371  
  • 19 Chu C. Liu B. Watson D. Szu S. Bryla D. Shiloach J. Schneerson R. Robbins JB. Infect. Immun.  1991,  59:  4450 
  • 20 Bethell GS. Ayers JS. Hancock WS. Hearn MTW. J. Biol. Chem.  1979,  254:  2572 
  • 21 Marburg S. Jorn D. Tolman RL. Arison B. McCauley J. Kniskern PJ. Hagopian A. Vella PP. J. Am. Chem. Soc.  1986,  108:  5282 
  • 22 Egan W. Ann. Rep. Med. Chem.  1993,  28:  257 
  • 23 Gray GR. Arch. Biochem. Biophys.  1974,  163:  426 
  • 24 Paoletti LC. Kasper DL. Michon F. DiFabio JL. Holme K. Jennings HJ. Wessels M. J. Biol. Chem.  1990,  265:  18278 
  • 25 Paulsen H. Paal M. Carbohydr. Res.  1983,  113:  203 
  • 26 Roy R. Katzenellenbogen E. Jennings HJ. Can. J. Biochem. Cell Biol.  1984,  62:  270 
  • 27 Liu XC. Dordick JS. J. Am. Chem. Soc.  1999,  121:  466 
  • 28 Constantino P. Viti S. Podda A. Velmonte MA. Nencioni L. Rappuoli R. Vaccine  1992,  10:  691 
  • 29 Arakatsu Y. Ashwell G. Kabat EA. J. Immunol.  1966,  97:  858 
  • 30 Schneerson R. Barrera O. Sutton A. Robbins JB. J. Exp. Med.  1980,  152:  361 
  • 31 Black S. Shinefield H. Fireman B. Lewis E. Ray P. Hansen JR. Elvin L. Ensor KM. Hackell J. Siber G. Malinoski F. Madore D. Chang I. Kohberger R. Watson W. Austrian R. Edwards K. Pediatr. Infect. Dis. J.  2000,  19:  187 
  • 32 Lagergard T. Shiloach J. Robbins JB. Schneerson R. Infect. Immun.  1990,  58:  687 
  • 33 Lin FYC. Ho VA. Khiem HB. Trach DD. Bay PV. Thanh TC. Kossaczka Z. Bryla DA. Shiloach J. Robbins JB. Schneerson R. Szu SC. Lanh MN. Hunt S. Trinh L. Kaufman JB. N. Engl. J. Med.  2001,  344:  1263 
  • 34 Shinefield H. Black S. Fattom A. Horwith G. Rasgon S. Ordonez J. Yeoh H. Law D. Robbins JB. Schneerson R. Muenz L. Naso R. N. Engl. J. Med.  2002,  346:  491 
  • 35 Svenson SB. Lindberg AA. Infect. Immun.  1981,  32:  490 
  • 36 Anderson PW. Pichichero ME. Insel RA. Betts R. Eby R. Smith DH. J. Immunol.  1986,  137:  1181 
  • 37 Laferriere CA. Sood RK. deMuys JM. Michon F. Jennings HJ. Vaccine  1997,  15:  179 
  • 38 Pichichero ME. Porcelli S. Treanor J. Anderson P. Vaccine  1998,  16:  83 
  • 39 Glaudemans CPJ. Chem. Rev.  1991,  91:  25 
  • 40 Lindberg AA. Pal T. Vaccine  1993,  11:  168 
  • 41 Iversen ER. Colding H. Petersen L. Ngetich R. Shanks GD. Trans. R. Soc. Trop. Med. Hyg.  1998,  92:  30 
  • 42 Iwalokun BA. Gbenle GO. Smith SI. Ogunledun A. Akinsinde KA. Omonigbehin EA. J. Health Popul. Nutr.  2001,  19:  183 
  • 43 Lindberg AA. Karnell A. Weintraub A. Rev. Infect. Dis.  1991,  13:  S279 
  • 44 Passwell JH. Harlev E. Ashkenazi S. Chu CY. Miron D. Ramon R. Farzan N. Shiloach J. Bryla DA. Majadly F. Roberson R. Robbins JB. Schneerson R. Infect. Immun.  2001,  69:  1351 
  • 45 Konadu EY. Lin FYC. Ho VA. Thuy NTT. Bay PV. Thanh TC. Khiem HB. Trach DD. Karpas AB. Li J. Bryla DA. Robbins JB. Szu SC. Infect. Immun.  2000,  68:  1529 
  • 46 Pozsgay V. Angew. Chem. Int. Ed.  1998,  37:  138 
  • 47 Pozsgay V. J. Org. Chem.  1998,  63:  5983 
  • 48 Pozsgay V. Coxon B. Yeh H. Bioorg. Med. Chem.  1993,  1:  237 
  • 49 Pozsgay V. Pannell L. Carbohydr. Res.  1994,  258:  105 
  • 50 Pozsgay V. Glaudemans CPJ. Robbins JB. Schneerson R. Carbohydr. Res.  1993,  244:  259 
  • 51 Pozsgay V. J. Am. Chem. Soc.  1995,  117:  6673-6681  
  • 52 Pozsgay V. Tetrahedron: Asymmetry  2000,  11:  151 
  • 53 Pozsgay V. Coxon B. Carbohydr. Res.  1994,  257:  189 
  • 54 Pozsgay V. Jennings HJ. Carbohydr. Res.  1988,  179:  61 
  • 55 Schmidt RR. Jung K.-H. In Carbohydrates in Chemistry and Biology   Vol 1:  Ernst B. Hart GW. Sinaӱ P. Wiley-VCH; Weinheim: 2000.  p.5-59  
  • 56 Pozsgay V. Glaudemans CPJ. Robbins JB. Schneerson R. Tetrahedron  1992,  48:  10249 
  • 57 Pozsgay V. J. Org. Chem.  1999,  64:  7277 
  • 58 Pozsgay V. J. Carbohydr. Chem.  2001,  71:  659 
  • 59 Pedretti V. Veyrières A. Sinaӱ P. Tetrahedron  1990,  46:  77 
  • 60 Evans ME. Parrish FW. Carbohydr. Res.  1977,  54:  105 
  • 61 For a comprehensive review of solid phase-based oligosaccharide synthesis, see: Solid Support Oligosaccharide Synthesis and Combinatorial Carbohydrate Libraries   Seeberger PH. Wiley-Interscience; New York: 2002. 
  • 63 Pozsgay V. Org. Lett.  1999,  1:  477 
  • 65 Vaino AR. Szarek WA. Adv. Carbohydr. Chem. Biochem.  2001,  56:  9 
  • 66 Pozsgay V. Vieira NE. Yergey A. Org. Lett.  2002,  4:  3191 
  • 67 Hudlicky T. Koszyk FJ. Kutchan TM. Sheth JP. J. Org. Chem.  1980,  45:  5020 
  • 68 Pavliak V. Nashed EM. Pozsgay V. Kovac P. Karpas A. Chu CY. Schneerson R. Robbins JB. Glaudemans CPJ. J. Biol. Chem.  1993,  268:  25797 
  • 69 Miller CE. Karpas A. Schneerson R. Huppi K. Kovac P. Pozsgay V. Glaudemans CP. J. Molec. Immun.  1996,  33:  1217 
  • 70 Pozsgay V. Glaudemans CPJ. Robbins JB. Schneerson R. Bioorg. Med. Chem. Lett.  1992,  2:  255 
  • 71 Pozsgay V. Sari N. Coxon B. Carbohydr. Res.  1998,  308:  229 
  • 72 Coxon B. Sari N. Batta G. Pozsgay V. Carbohydr. Res.  2000,  324:  53 
  • 73 Nyholm P.-G. Mulard LA. Miller CE. Olin R. Glaudemans CPJ. Glycocobiology  2001,  11:  945 
  • 74 Pozsgay V. Chu C. Pannell L. Wolfe J. Robbins JB. Schneerson R. Proc. Natl. Acad. Sci. U.S.A.  1999,  96:  5194 
62

Anonymous referee 2002.

64

Berkin, A.; Pozsgay, V. In preparation.